mRNA Cocktail Erases Pancreatic Tumors in Half of Mice
A new mRNA-based immunotherapy has shown unprecedented success in animal models of pancreatic cancer. Researchers at UMass Chan Medical School developed a single injection combining five cytokine mRNAs and three tumor-associated antigens. In mice with pancreatic ductal adenocarcinoma, approximately 50% experienced complete tumor regression that lasted up to one year after treatment stopped. The therapy works by weakening the fibrotic barrier around tumors and training the immune system to recognize cancer cells, potentially creating long-term immune memory. While mouse results do not guarantee human success, the team is developing an IND-ready product for clinical trials.
Key points
- The experimental treatment combines mRNAs encoding five immune cytokines and three tumor-associated antigens into one injectable formulation.
- In a mouse model, about 50% of subjects achieved complete tumor regression, with no recurrence observed for up to one year after therapy ended.
- The therapy reduces fibrotic tissue surrounding tumors, allowing immune cells to access and attack cancer cells more effectively.
- Researchers believe the approach may create durable immune memory, preventing cancer recurrence even after treatment stops.
- The team is developing an IND-ready product to prepare for future human clinical trials, funded by the Pancreatic Cancer Alliance.
Background
This development follows earlier progress in mRNA cancer vaccines, including personalized vaccines from Moderna and Merck that showed promise against melanoma and other cancers. Previous studies also explored localized immunotherapy using engineered bacteria to deliver immune signals directly to pancreatic tumors. These efforts highlight ongoing attempts to overcome the biological barriers that make pancreatic cancer resistant to standard immunotherapies.
How outlets are covering it
SciTechDaily emphasizes the unprecedented durability of the response in mice, noting that previous treatments often led to cancer recurrence. The outlet highlights the potential for the mRNA platform to be adapted for other immune-resistant cancers by swapping sequences. BioWorld News and Inside Precision Medicine focus on a different but related strategy: using IL-21 mimetics to extend the benefits of KRAS inhibitors in pancreatic cancer. While the UMass Chan study uses a direct mRNA cocktail to activate immunity, the Harvard-led research aims to lock in gains from existing drugs. Both approaches address the challenge of durable remission in pancreatic cancer but use distinct mechanisms.
Why it matters
Pancreatic cancer has a five-year survival rate of only 13% across all stages, with stage IV survival at 3%. Current immunotherapies often fail because tumors create a hostile microenvironment that blocks immune cells. This new mRNA approach could overcome these barriers by delivering immune signals directly to the tumor site. If successful in humans, it could offer a durable treatment option for a currently incurable disease and provide a modular platform for other cancers.
What to watch
Researchers are developing an IND-ready product of the mRNA cocktail to prepare for clinical trials. The team aims to test the therapy in humans, though they acknowledge the transition from mice to patients is uncertain. If successful, the platform could be adapted for other immune-resistant cancers by changing the mRNA sequences to target different tumors.
- Pancreatic Cancer Disappears in Mice After New mRNA Immunotherapy SciTechDaily
- IL-21 mimetic drives durable remission in PDAC BioWorld News
- Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer Medical Xpress
- New Immunotherapy Strategy Extends KRAS Inhibitor Response in Pancreatic Cancer Inside Precision Medicine
Want the full story? Read the original reporting
Read on SciTechDaily